phageal obturator may-be inserted to prevent the gastric contents reaching the pharynx while giving a clear airway.' Such devices have been used successfully on considerable numbers of patients,2 but they are not free from hazards.3 If they are to be available in the event ofdifficulty, anaesthetists must know how to use them and the problems they may pose.
The advice for inexperienced anaesthetists is-or should be-clear cut. Firstly, they should be sure the tube is really necessary in the first place. Secondly, they have to be ready to decide sooner rather than later that they cannot intubate a patient and have a readily applicable drill for such an eventuality. Thirdly, they should maintain a high level of suspicion for oesophageal placement. And, fourthly, they should be competent at artificial ventilation using a mask, airway, and bag.
Non-anaesthetists attempting cardiopulmonary resuscitation should attempt to intubate only if they know they are competent and accept proper placement only if all the signs are right. They should never intubate as the first intervention -mouth to mouth respiration comes first. Finally, all those concerned with deaths should insist that the tube is left in situ. The pathologist will then be able to confirm its position-and so stop endless and fruitless arguments. 
AIDS in primates
Several species of old world African and Asian non-human primates are naturally infected with simian T lymphotropic viruses (STLV) types I and III, which are closely related to the human counterpart T lymphotropic viruses HTLV-I and LAV/HTLV-III. The exogenous type C retrovirus isolated from captive macaque monkeys with an immune deficiency syndrome (simian AIDS) in the United States has been designated STLV-III mac. There are striking similarities between this virus and LAV/HTLV-III, the causative agent of the human acquired immune deficiency syndrome (AIDS). These include growth characteristics, morphology, T4 cell tropism, similar size of viral structural proteins, and serological cross reactivity ofviral proteins. More recently a virus which is also related to LAV/HTLV-III was isolated'from healthy African green monkeys (Cercopithecus aethiops) and designated STLV-III agm. Antibodies to this virus are found frequently (5-70% or more, average 40%) in serum from African green monkeys originating from central and other regions ofAfrica (K N Tsiquaye, A J Zuckerman, unpublished observations).
The main proteins of this simian virus are also similar in molecular weight to the main gag and env encoded proteins of LAV/HTLV-III and are recognised by reference LAV/ HTLV-III human serum as well as by monoclonal antibodies to the main core protein, p24, of the human virus.' Though we do not know how long such viruses have been present in African green monkeys in Africa, limited serological evidence suggests that antibody to STLV-III has been present for at least 10 years.2
These findings are particularly important in relation to the production of vaccines and reagents in monkey kidney cell cultures and the use of these cultures in diagnostic virology. For example, most of the oral attenuated live poliomyelitis vaccine used throughout the world is produced in primary kidney cultures from African green monkeys and in some countries from rhesus monkeys. The World Health Organisation therefore convened two informal meetings of experts to discuss the findings of simian T lymphotropic viruses and consider the implications. The conclusions were reassuring.3
Firstly, during the 1970s representative bulk and final preparations of live poliomyelitis vaccines prepared in African green monkey kidney cultures were tested for the presence of retroviruses by reverse transcriptase assays; and primary monkey kidney cell cultures, including those from African green monkeys, were examined after chemical induction by electron microscopy for virus-like particles and for particle associated reverse transcriptase activity. No evidence was found for the presence of retroviruses.
Secondly, current tests of World Health Organisation vaccine seed stocks of poliovirus types 1, 2, and 3 as well as more than 20 batches of vaccine in Europe and North America yielded no evidence of retroviruses. In addition 250 recipients of vaccine in Europe and North America were tested for LAV/HTLV-III antibodies and found. to be negative. Thirty of these recipients were tested and were negative for antibodies to STLV-III.
Thirdly, long term and continuing follow up of recipients of live poliomyelitis vaccine suggests the absence of adverse effects potentially associated with retrovitus.
We have not, however, heard the last of simian T lymphotropic viruses. Antibodies to a virus which is almost indistinguishable from STLV-III agm have recently been found in apparently healthy people living in west Africa.4 Studies of the molecular structure and biology of these simian viruses will yield a wealth-of information relevant to the study of the human counterpart viruses. 
